Document is current
Any future updates will be listed below
-
Authors
Wartak, Andreas
Garber, John G.
Yuan, Qian
Shreffler, Wayne G.
Hesterberg, Paul E.
Katz, Aubrey J.
Osman, Hany
Leung, Hui Min
Gao, Anna
Otuya, David O.
Grant, Catriona
Gardecki, Joseph A.
Nishioka, Norman
Tearney, Guillermo J.
Apiou-Sbirlea, Gabriela
-
Funding
Funding for this research was provided by:
National Institutes of Health (R01DK118509)
National Institutes of Health (R01DK100569)
National Institutes of Health (R01CA184102)
National Institutes of Health (R01DK091923)
National Institutes of Health (R01CA103769)
National Institutes of Health (R21CA141884)
National Institutes of Health (R21CA122161)
NinePoint Medical
CN USA Biotech Holdings
John and Dottie Remondi Foundation
Hazard Family Foundation
American Partnership for Eosinophilic Disorders
- License Information
-
More Information
Article History
Received: 19 October 2020
Accepted: 8 December 2020
First Online: 6 January 2021
Ethics approval and consent to participate
: For the EoE biopsy study patient selection, consenting, biopsy collection, imaging, and processing were performed according to the MGH’s Internal Review Board approved protocol 2015P000328. The swine esophageal tissue study was performed according to the MGH’s Institutional Animal Care and Use Committee approved protocol 2014N000300.
: Not applicable.
: G.J.T. has a financial/fiduciary interest in SpectraWave, a company developing an OCT-NIRS intracoronary imaging system and catheter. His financial/fiduciary interest was reviewed and is managed by the Massachusetts General Hospital and MGB HealthCare in accordance with their conflict of interest policies. G.J.T. receives royalties from Terumo Corporation, iLumen, and Nidek. G.J.T. has a consulting relationship with Spectrawave. G.J.T. receives sponsored research funding from iLumen, Canon Inc., AstraZeneca, Vertex, VivoLight, Hamamatsu, CN USA Biotech Holdings, Wayvector, Translate Bio, Boston Scientific.
